Table 1 Outcomes and events after BrECAPP and BrECADD treatment.

From: Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

 

6 × BrECAPP

(N = 49)

6 × BrECADD

(N = 52)

Observation time

 Observation time for disease status, median

31 months

34 months

 Observation time for survival status, median

35 months

34 months

3-year survival estimates

 Progression-free survival

90.2% (80.9–99.5%)

89.7% (81.0–98.3%)

 Overall survival

100%

95.4% (89.2–100%)

Hodgkin lymphoma eventsa

Any Hodgkin lymphoma event

4

(8%)

4

(8%)

 Progressionb

0

 

3

(6%)

 Relapsec

4

(8%)

1

(2%)

Number of Hodgkin lymphoma events

 1

4

(8%)

2

(4%)

 2

0

 

2

(4%)

Second-line treatment

 High-dose chemotherapy and autologous stem cell transplantation

4

(8%)

4

(8%)

Causes of death

Any event

0

 

2

(4%)

 Hodgkin lymphoma

0

 

1

(2%)

 Accident

0

 

1

(2%)

Second primary malignancies

Any event

0

 

0

 
  1. Data are median, % (95%-CI), or n (%). Only patients eligible for efficacy analyses are shown; 3 of 104 patients were excluded because they did not receive any study treatment (n = 2) or terminated treatment due to disconfirmation of advanced-stage disease (n = 1).
  2. BrECAPP brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, procarbazine, prednisone, BrECADD brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone.
  3. aDefined as biopsy-proven disease progression or relapse of cHL.
  4. bDefined as the occurrence of new lesions during treatment or at least 1 known lesion that increased by more than 25% in diameter during treatment or within 3 months after the end of systemic study treatment.
  5. cDefined as the appearance of new lesions or the reappearance of initial lesions at least 3 months after the end of systemic study treatment.
Back to article page